Long-Term Incentive Plans (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended									12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014		Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2000
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation										$ 459,049	$ 321,750	$ 215,377
Selling, general, and administrative										838,526	519,267	346,393
Deferred Tax Assets, Net, Noncurrent	$ 461,945				$ 315,416					461,945	315,416
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Assets	5,609,132				3,837,672					5,609,132	3,837,672
Additional paid-in capital	3,099,526				2,450,782					3,099,526	2,450,782
Retained Earnings (Accumulated Deficit)	852,700				216,644					852,700	216,644
Stockholders' Equity Attributable to Parent	3,654,837				2,550,251					3,654,837	2,550,251	1,964,716	$ 1,256,618
Liabilities and Equity	5,609,132				3,837,672					5,609,132	3,837,672
Costs and Expenses										2,851,812	1,995,638	1,361,695
Operating Income (Loss)										1,251,916	823,919	743,050
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest										1,225,097	761,235	696,382
Income Tax Expense (Benefit)										589,041	423,109	282,644
Net Income	$ 154,994	$ 210,398	$ 194,643	$ 76,021	$ 90,095	$ 83,375	[1]	$ 96,351	$ 68,305	$ 636,056	$ 338,126	$ 413,738
Earnings Per Share, Basic	$ 1.49	$ 2.04	$ 1.89	$ 0.74	$ 0.89	$ 0.83		$ 0.96	$ 0.69	$ 6.17	$ 3.36	$ 4.23
Net income per share - diluted	$ 1.34	$ 1.82	$ 1.69	$ 0.66	$ 0.78	$ 0.73		$ 0.85	$ 0.61	$ 5.52	$ 2.98	$ 3.72
Increase (Decrease) in Deferred Income Taxes										$ 121,623	$ 53,276	$ (62,195)
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum term of awards										10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares outstanding at beginning of period				21,506,260						21,506,260
Number of shares granted										4,495,487	3,913,368	3,937,989
Number of shares forfeited										(318,952)
Number of shares expired										(363)
Number of shares exercised										(2,516,663)
Number of shares outstanding at end of period	23,165,769				21,506,260					23,165,769	21,506,260
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted average exercise price - outstanding at beginning of period				$ 158.54						$ 158.54
Weighted average exercise price - granted										537.29	$ 385.33	$ 263.77
Weighted average exercise price - forfeited										292.14
Weighted average exercise price - expired										92.20
Weighted average exercise price - exercised										98.26
Weighted average exercise price - outstanding at end of period	$ 236.75				$ 158.54					$ 236.75	$ 158.54
Weighted average remaining contractual term (in years) - outstanding										6 years 9 months 24 days
Instrinsic value - outstanding	$ 7,209,994,851									$ 7,209,994,851
Number of shares vested and expected to vest	22,635,728									22,635,728
Weighted average execise price - vested and expected to vest	$ 231.75									$ 231.75
Weighted average remaining contractual term - vested and expected to vest										6 years 9 months 5 days
Intrinsic value - vested and expected to vest	$ 7,156,754,651									$ 7,156,754,651
Number of shares exercisable	13,212,236									13,212,236
Weighted average exercise price - exercisable	$ 103.67									$ 103.67
Weighted average remaining contractual term - exercisable										5 years 2 months 23 days
Intrinsic value - exercisable	$ 5,852,659,560									$ 5,852,659,560
Total intrinsic value - of stock options exercised										$ 1,031,600	$ 1,081,200	$ 727,500
Exercise Price Equal to Market Price [Abstract]
Number of Options Granted (shares)										4,495,487	3,913,368	3,937,989
Weighted Average Exercise Price (dollars per share)										$ 537.29	$ 385.33	$ 263.77
Weighted Average Fair Value										$ 181.65	$ 140.38	$ 104.90
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]
Expected volatility										35.00%	39.00%	42.00%
Expected lives from grant date										5 years 1 month 1 day	5 years 2 months 11 days	5 years 4 months 1 day
Expected dividend yield										0.00%	0.00%	0.00%
Risk-free interest rate										1.68%	1.62%	1.73%
Stock options | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period										3 years
Stock options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period										4 years
Phantom stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Period within vesting date that awards may be received										30 days
Non-performance based stock options
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Non-cash stock-based compensation expense										$ 443,700	$ 306,100	$ 193,400
Unrecognized stock-based compensation cost, net of estimated forfeitures	$ 962,600									$ 962,600
Weighted average period for recognition of total unrecognized compensation expense (in years)										2 years
Performance-based stock options
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Non-cash stock-based compensation expense											4,100	$ 8,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Number	0									0		770,250
Restricted stock
Employee Service Share-based Compensation, Aggregate Disclosures [Abstract]
Non-cash stock-based compensation expense										$ 15,300	$ 11,500	$ 14,000
Unrecognized stock-based compensation cost, net of estimated forfeitures	$ 33,900									$ 33,900
Weighted average period for recognition of total unrecognized compensation expense (in years)										2 years 1 month
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]
Number of shares outstanding at beginning of period				546,060						546,060
Number of shares granted										27,520
Number of shares vested										(31,880)
Number of shares outstanding at end of period	541,700				546,060					541,700	546,060
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Weighted average grant date fair value at beginning of period				$ 115.26						$ 115.26
Weighted average grant date fair value - granted										540.40
Weighted average grant date fair value - vested										164.65
Weighted average grant date fair value at end of period	$ 133.96				$ 115.26					$ 133.96	$ 115.26
Long-Term Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance					16,485,333						16,485,333
Number of shares available for future grants	9,711,439									9,711,439
Long-Term Incentive Plan 2000 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance														35,397,043
Common Stock
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Number of shares exercised										(2,457,000)	(3,468,000)	(3,052,000)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Stockholders' Equity Attributable to Parent	$ 106				$ 102					$ 106	$ 102	$ 97	$ 95
Common Stock | Long-Term Incentive Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized for issuance					4,485,333						4,485,333
Scenario, Previously Reported [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation											$ 307,238	198,399
Selling, general, and administrative					$ 143,743						504,755	329,415
Deferred Tax Assets, Net, Noncurrent					316,104						316,104
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Assets					3,871,827						3,871,827
Additional paid-in capital					2,404,118						2,404,118
Retained Earnings (Accumulated Deficit)					255,382						255,382
Stockholders' Equity Attributable to Parent					2,542,325						2,542,325
Liabilities and Equity					3,871,827						3,871,827
Costs and Expenses					554,962						1,981,126	1,344,717
Operating Income (Loss)					247,367						838,431	760,028
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest					221,287						775,747	713,360
Income Tax Expense (Benefit)					111,111						427,673	288,998
Net Income					$ 110,176						$ 348,074	$ 424,362
Earnings Per Share, Basic					$ 1.09						$ 3.46	$ 4.33
Net income per share - diluted					$ 0.96						$ 3.07	$ 3.81
Increase (Decrease) in Deferred Income Taxes											$ (66,604)	$ 63,601
Restatement Adjustment [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation											14,512	16,978
Selling, general, and administrative					$ 31,564
Deferred Tax Assets, Net, Noncurrent					22,152						22,152
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Assets					22,152						22,152
Additional paid-in capital					60,890						60,890
Retained Earnings (Accumulated Deficit)					(38,738)						(38,738)
Stockholders' Equity Attributable to Parent					22,152						22,152
Liabilities and Equity					22,152						22,152
Costs and Expenses					31,564						14,512	16,978
Operating Income (Loss)					(31,564)						(14,512)	(16,978)
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest					(31,564)						(14,512)	(16,978)
Income Tax Expense (Benefit)					(11,483)
Net Income					$ (20,081)						$ (9,948)	$ (10,624)
Earnings Per Share, Basic					$ (0.20)						$ (0.10)	$ (0.10)
Net income per share - diluted					$ (0.18)						$ (0.09)	$ (0.09)
Increase (Decrease) in Deferred Income Taxes											$ (4,564)	$ (6,354)
Revised [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation											321,750	215,377
Selling, general, and administrative					$ 175,307						519,267	346,393
Deferred Tax Assets, Net, Noncurrent					338,256						338,256
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]
Assets					3,893,979						3,893,979
Additional paid-in capital					2,465,008						2,465,008
Retained Earnings (Accumulated Deficit)					216,644						216,644
Stockholders' Equity Attributable to Parent					2,564,477						2,564,477
Liabilities and Equity					3,893,979						3,893,979
Costs and Expenses					586,526						1,995,638	1,361,695
Operating Income (Loss)					215,803						823,919	743,050
Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest					189,723						761,235	696,382
Income Tax Expense (Benefit)					99,628						423,109	282,644
Net Income					$ 90,095						$ 338,126	$ 413,738
Earnings Per Share, Basic					$ 0.89						$ 3.36	$ 4.23
Net income per share - diluted					$ 0.78						$ 2.98	$ 3.72
Increase (Decrease) in Deferred Income Taxes											$ (71,168)	$ 57,247

[1] Net income in the third quarter of 2014 included a $40.6 million incremental charge related to the Branded Prescription Drug Fee based on final regulations issued by the IRS in July 2014 as described in Note 2 above.